Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

Table 2 Univariate analysis of disease-free survival by patient and tumor characteristics, n (%)

Population characteristics	Relapse (n = 75)	No relapse (n = 102)	P value	Univariate analysis of DFS, months	P value	Multivariate analysis P value
Age, years			0.41		0.080	HR: 1.64, P = 0.04, CI: 1.019-2.652
< 65	38 (50.7)	58 (56.9)		27.9
≥ 65	37 (49.3)	44 (43.1)		18.5
Gender			0.32		0.110
Male	50 (66.7)	75 (73.5)		33.4
Female	25 (33.3)	27 (26.5)		19.0
ECOG PS			0.04		0.070
0	39 (52.0)	68 (66.7)		33.4
1	36 (48.0)	34 (33.3)		19.9
Body mass index			< 0.001		< 0.001
≥ 25	25 (33.3)	64 (64.6)		NA
< 25	50 (66.7)	35 (35.4)		18.5
Histological type			< 0.001		< 0.001
Adeno	49 (65.3)	92 (90.2)		37.3
Signet ring cell	26 (34.7)	10 (9.8)		15.9
c-T stage			< 0.001		< 0.001
1-2	2 (2.7)	27 (26.5)		NA
3-4	73 (97.3)	75 (73.5)		20.9
c-N stage			0.006		0.011
Negative	4 (5.3)	20 (19.6)		NA
Positive	71 (94.7)	82 (80.4)		22.7
c-stage			< 0.001		< 0.001
1-2	6 (8.0)	41 (40.2)		NA
3	69 (92.0)	61 (59.8)		18.8
Grade			< 0.001		< 0.001
I-II	24 (32.0)	63 (61.8)		NA
III	51 (68.0)	39 (38.2)		17.7
HER-2 status			0.50		0.330
Negative	67 (93.1)	91 (95.8)		27.0
Positive	5 (6.9)	4 (4.2)		15.4
MSI			0.44		0.660
Low	59 (93.7)	83 (90.2)		24.0
High	4 (6.3)	9 (9.8)		20.9
pT stage			< 0.001		< 0.001
0-2	11 (14.7)	53 (52.0)		NA
3-4	64 (85.3)	49 (48.0)		18.8
pN stage			< 0.001		< 0.001
N0-1	21 (28.0)	79 (77.5)		NA
N2-3	54 (72.0)	23 (22.5)		14.0
yp stage			< 0.001		< 0.001
0-1	6 (8.0)	45 (44.1)		NA
2-3	69 (92.0)	57 (55.9)		18.8
Lymphovascular invasion						HR: 4.20, P < 0.001, CI: 2.000-8.860
No	10 (13.3)	60 (58.8)	< 0.001	NA	< 0.001
Yes	65 (86.7)	42 (41.2)		16.6
Perineural invasion			< 0.001		< 0.001	HR: 1.87, P = 0.03, CI: 1.043-3.374
No	19 (25.3)	71 (69.6)		NA
Yes	56 (74.7)	31 (30.4)		16.7
Surgery			< 000.1		< 0.001
R0	59 (78.7)	98 (96.1)		33.4
R1	16 (21.3)	4 (3.9)		13.0
Becker regression score			< 0.001		< 0.001
1	6 (8.0)	36 (35.3)		NA
2-3	69 (92.0)	66 (64.7)		20.9
Adjuvant therapy			0.001		< 0.001	HR: 3.58, P < 0.001, CI: 2.004-6.409
Yes	56 (74.7)	94 (92.2)		36.0
No	19 (25.3)	8 (7.8)		8.3
Post operative radiotherapy			0.014		0.120
No	41 (54.7)	74 (72.5)		44.9
Yes	34 (45.3)	28 (27.5)		19.0
NLR (median = 2.06)			0.350		0.300
Low	32 (43.8)	52 (51.0)		26.9
High	41 (56.2)	50 (49.0)		27.0
PLR (median = 128.4)			0.310		0.240
Low	33 (45.2)	54 (52.9)		36.0
High	40 (54.8)	48 (47.1)		27.0
Anemia, Hb < 12 g/dL			0.360		0.500
No	33 (44.0)	38 (37.3)		24.0
Yes	42 (56.0)	64 (62.7)		33.4
Albumin, 3.5 g/L			0.016		0.014	HR: 2.73, P = 0.01, CI: 1.278-5.858
High	64 (87.7)	98 (97.0)		27.9
Low	9 (12.3)	3 (3.0)		12.5
CEA			0.69		0.51
< 5 ngr/L	49 (73.1)	64 (70.3)		26.9
> 5 ngr/L	18 (26.9)	27 (29.7)		33.4

DFS: Disease-free survival; HR: Hazard ratio; CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; c-T: Clinic tumor stage; c-N: Clinic lymph node stage; MSI: Microsatellite instability; pT: Pathological tumor stage; pN: Pathological node stage; yp stage: Post neoadjuvant therapy stage; NLR: Neutrophil-to-lymphocyte count; PLR: Platelet-to-lymphocyte count; CEA: Carcinoembryonic antigen; NA: Not available.